KLP Kapitalforvaltning AS Invests $209,000 in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

KLP Kapitalforvaltning AS purchased a new stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 11,100 shares of the company’s stock, valued at approximately $209,000.

A number of other institutional investors have also recently made changes to their positions in NRIX. Teacher Retirement System of Texas raised its position in Nurix Therapeutics by 18.4% during the fourth quarter. Teacher Retirement System of Texas now owns 16,263 shares of the company’s stock valued at $306,000 after purchasing an additional 2,532 shares during the period. Nikko Asset Management Americas Inc. boosted its holdings in shares of Nurix Therapeutics by 42.8% in the 4th quarter. Nikko Asset Management Americas Inc. now owns 789,222 shares of the company’s stock worth $14,869,000 after purchasing an additional 236,620 shares during the period. Raymond James Financial Inc. bought a new position in shares of Nurix Therapeutics during the 4th quarter valued at approximately $1,026,000. Proficio Capital Partners LLC bought a new position in shares of Nurix Therapeutics during the 4th quarter valued at approximately $376,000. Finally, Victory Capital Management Inc. lifted its position in Nurix Therapeutics by 179.5% in the fourth quarter. Victory Capital Management Inc. now owns 60,212 shares of the company’s stock worth $1,134,000 after buying an additional 38,672 shares during the last quarter.

Nurix Therapeutics Trading Up 0.3 %

Shares of Nurix Therapeutics stock opened at $9.72 on Tuesday. The stock’s fifty day moving average price is $15.25 and its 200-day moving average price is $19.75. The firm has a market cap of $741.01 million, a P/E ratio of -3.36 and a beta of 2.23. Nurix Therapeutics, Inc. has a 12 month low of $8.60 and a 12 month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last issued its earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. Analysts forecast that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on NRIX. Stephens reiterated an “overweight” rating and set a $31.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday, January 21st. BTIG Research began coverage on shares of Nurix Therapeutics in a report on Tuesday, December 10th. They set a “buy” rating and a $35.00 price target on the stock. Stifel Nicolaus raised their price objective on shares of Nurix Therapeutics from $34.00 to $36.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. Leerink Partners began coverage on Nurix Therapeutics in a research note on Monday, March 17th. They set a “market perform” rating and a $16.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $36.00 price target on shares of Nurix Therapeutics in a research note on Wednesday, April 2nd. Three investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $30.88.

Insider Activity

In related news, insider Gwenn Hansen sold 3,690 shares of the company’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $73,246.50. Following the completion of the sale, the insider now directly owns 55,937 shares in the company, valued at $1,110,349.45. This represents a 6.19 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Houte Hans Van sold 5,825 shares of the firm’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $14.49, for a total value of $84,404.25. Following the sale, the chief financial officer now directly owns 33,724 shares in the company, valued at approximately $488,660.76. The trade was a 14.73 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 12,326 shares of company stock worth $213,449. Corporate insiders own 7.20% of the company’s stock.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.